In this FOX4 News interview, Dallas health care attorney David M. Walsh, IV discusses legal strategies that the producer of GranuFlo and NaturaLyte might use in defending itself against charges that its drug caused the death of patients. “The FDA approval (of the drug) would be one defense,” says Mr. Walsh, a partner at Dallas-based Chamblee, Ryan, Kershaw & Anderson, P.C. “A second defense would be looking at plaintiffs’ individual conditions, saying the drug didn’t cause it, because these are dialysis patients, and they were very sick to begin with. The third way would be to attribute fault to the doctors or health care providers, because the FDA recall mentions that it was given at inappropriate doses.” Mr. Walsh is not involved in the GranuFlo/NaturaLyte litigation.
The news piece can be found here.
Attorney: David M. Walsh, IV
